As of Friday close, Ironwood Pharmaceuticals Inc.’s (NASDAQ:IRWD) stock was down -$0.12, moving down -1.28 percent to $9.29. The average number of shares traded per day over the past five days has been 3,477,280 shares. 3 times new highs have been achieved over the past 5 days, with a $0.95 gain in that time frame. In the last twenty days, the average volume was 3,185,560, while in the previous 50 days, it was 2,530,014.
Since last month, IRWD stock rose 1.53%. Shares of the company fell to $8.07 on 09/11/23, the lowest level in the past month. A 52-week high of $12.66 was reached on 01/06/23 after having rallying from a 52-week low of $8.07. Since the beginning of this year, IRWD’s stock price has dropped by -25.02% or -$3.10, and marked a new high 3 times. However, the stock has declined by -26.62% since its 52-week high.
IRWD stock investors should be aware that Ironwood Pharmaceuticals Inc. (IRWD) stock had its last reported insider trading activity 8 days ago on Sep 15. Emany Sravan Kumar, the SVP, Chief Financial Officer of the company, purchased of 36,072 shares for $8.32 on Sep 15. It resulted in a $300,119 investment by the insider. John Minardo sold 7,045 shares at an average price of $10.04 on Aug 14. The insider now owns 192,195 shares following the transaction. On Aug 14, Principal Accounting Officer Silver Ronald sold 1,976 shares at $10.04 apiece. The transaction was valued at $19,839.
Financial Health
In the three months ended June 29, Ironwood Pharmaceuticals Inc.’s quick ratio stood at 1.00, while its current ratio was 1.00, showing that the company is able to pay off its debt. Based on annual data, IRWD earned $410.6 million in gross profit and brought in $410.6 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 16.50%. Return on equity (ROE) for the past 12 months was -228.70%.
In Ironwood Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $400.0 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. IRWD’s revenue rose 9.45% to $104.06 million during the quarter, while net income inched up to $107.38 million. While analysts expected Ironwood Pharmaceuticals Inc. to report $0.25 quarterly earnings, the actual figure was -$6.71 per share, beating the consensus estimate by -2,784.00%. During the quarter, the company generated -$1.08 billion in EBITDA. The liabilities of Ironwood Pharmaceuticals Inc. were 950.0 million at the end of its most recent quarter ended June 29, and its total debt was $815.75 million. The value of shareholders’ equity is $156.03 million.
Technical Picture
This quick technical analysis looks at Ironwood Pharmaceuticals Inc.’s (IRWD) price momentum. With a historical volatility rate of 47.76%, the RSI 9-day stood at 58.11% on 22 September.
With respect to its five-day moving average, the current Ironwood Pharmaceuticals Inc. price is up by +11.39% percent or $0.95. At present, IRWD shares trade +1.75% above its 20-day simple moving average and -12.93% percent below its 100-day simple moving average. However, the stock is currently trading approximately -10.07% below its SMA50 and -22.58% below its SMA200.
Stochastic coefficient K was 80.71% and Stochastic coefficient D was 75.24%, while ATR was 0.41. Given the Stochastic reading of 79.67% for the 14-day period, the RSI (14) reading has been calculated as 52.32%. As of today, the MACD Oscillator reading stands at 0.43, while the 14-day reading stands at 0.55.
Analyst Ratings
CapitalOne launched its rating on Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) to an Overweight in a note to investors on September 02, 2022. Ironwood Pharmaceuticals Inc. (IRWD) has been rated Overweight by analysts. According to 0 brokerage firms, IRWD is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Ironwood Pharmaceuticals Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $15.00, the current consensus forecast for the stock is $9.00 – $20.00. Based on these forecasts, analysts predict Ironwood Pharmaceuticals Inc. (IRWD) will achieve an average price target of $14.67.
